Lipigo 40 Tablet contains Rosuvastatin 40mg, a potent HMG-CoA reductase inhibitor used primarily for the management of hypercholesterolemia and mixed dyslipidemia. Rosuvastatin acts by selectively inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in the biosynthesis of cholesterol in the liver, leading to a significant reduction in low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels. This medication is indicated for patients with primary hyperlipidemia, including heterozygous familial hypercholesterolemia, and for the prevention of cardiovascular disease in individuals at high risk. Lipigo 40 Tablet has been shown to effectively increase high-density lipoprotein cholesterol (HDL-C) and lower triglycerides, contributing to improved lipid profiles. It is recommended to be administered once daily, with or without food, preferably at the same time each day to maintain consistent plasma levels. Prior to initiation, baseline liver function tests and lipid profiles should be obtained, with periodic monitoring during therapy. Caution is advised in patients with hepatic impairment, renal dysfunction, or a history of muscle disorders. Common adverse effects may include myalgia, headache, and gastrointestinal disturbances. Patients should be counseled on the importance of adherence to lifestyle modifications alongside pharmacotherapy for optimal outcomes.